Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges

被引：47
作者：
Mahajan, Priya [1 ,2 ]
Casanova, Michela [3 ]
Ferrari, Andrea [3 ]
Fordham, Ashleigh [4 ]
Trahair, Toby [4 ,5 ,6 ]
Venkatramani, Rajkumar [1 ,2 ]
机构：
[1] Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, 6701 Fannin St,Suite 1510, Houston, TX 77030 USA
[2] Baylor Coll Med, Texas Childrens Hematol Ctr, Dept Pediat, 6701 Fannin St,Suite 1510, Houston, TX 77030 USA
[3] Fdn IRCCS Ist Nazl Tumori, Pediat Oncol Unit, Milan, Italy
[4] UNSW Sydney New South Wales, Lowy Canc Res Ctr C25, Childrens Canc Inst, Kensington, NSW, Australia
[5] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia
[6] UNSW Med, Sch Womens & Childrens Hlth, Kensington, NSW, Australia
来源：
CURRENT PROBLEMS IN CANCER | 2021年 / 45卷 / 04期
基金：
英国医学研究理事会;
关键词：
Inflammatory myofibroblastic tumor; rare tumor; pediatrics; molecular profiling; targeted therapy; crizotinib; ALK inhibition; ANAPLASTIC LYMPHOMA-KINASE; PLASMA-CELL GRANULOMA; ALK EXPRESSION; GENE REARRANGEMENT; RANBP2; GENE; FUSION; INHIBITOR; ROS1; PSEUDOTUMORS; CRIZOTINIB;
D O I：
10.1016/j.currproblcancer.2021.100768
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor of intermediate malignant potential that predominantly affects children, adolescents and young adults. IMT has a predilection for the lung, abdomen, pelvis, and retroperitoneum, however, can affect any part of the body. IMT is typically localized, and multifocal or metastatic disease is uncommon. Complete surgical resection is the treatment of choice when feasible. There is no established standard of care for unresectable and advanced IMT. Approximately half of IMTs harbor anaplastic lymphoma kinase (ALK) gene rearrangements, and fusions involving ROS1, PDGFR beta, RET and NTRK have also been described. Given the molecular landscape of IMT, management of these tumors has evolved to include tyrosine kinase inhibitors and novel targeted therapeutics. This review highlights the molecular characteristics, evolution of targeted therapies and the remaining challenges in the management of IMT. (C) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页数：15
相关论文
共 91 条
  • [1] Inflammatory Myofibroblastic Tumors in Childhood A Report From the Italian Cooperative Group Studies
    Alaggio, Rita
    Cecchetto, Giovanni
    Bisogno, Gianni
    Gambini, Claudio
    Calabro, Maria Luisa
    Inserra, Alessandro
    Boldrini, Renata
    De Salvo, Gian Luca
    d'Amore, Emanuele S. G.
    Dall'lgna, Patrizia
    [J]. CANCER, 2010, 116 (01) : 216 - 226
  • [2] How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature
    Alan, Ozkan
    Kuzhan, Okan
    Koca, Sinan
    Telli, Tugba Akin
    Tuylu, Tugba Basoglu
    Ercelep, Ozlem
    Filinte, Deniz
    Sengul, Yildiz
    Arikan, Huseyin
    Kaya, Serap
    Babacan, Nalan Akgul
    Dane, Faysal
    Yumuk, Perran Fulden
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (04) : 1011 - 1018
  • [3] ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors
    Alassiri, Ali H.
    Ali, Rola H.
    Shen, Yaoqing
    Lum, Amy
    Strahlendorf, Caron
    Deyell, Rebecca
    Rassekh, Rod
    Sorensen, Poul H.
    Laskin, Janessa
    Marra, Marco
    Yip, Stephen
    Lee, Cheng-Han
    Ng, Tony L.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (08) : 1051 - 1061
  • [4] Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions
    Ambati, Srikanth R.
    Slotkin, Emily K.
    Chow-Maneval, Edna
    Basu, Ellen M.
    [J]. JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 6
  • [5] Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement
    Antonescu, Cristina R.
    Suurmeijer, Albert J. H.
    Zhang, Lei
    Sung, Yun-Shao
    Jungbluth, Achim A.
    Travis, William D.
    Al-Ahmadie, Hikmat
    Fletcher, Christopher D. M.
    Alaggio, Rita
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (07) : 957 - 967
  • [6] The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study
    Applebaum, H
    Kieran, MW
    Cripe, TP
    Coffin, CM
    Collins, MH
    Kaipainen, A
    Laforme, A
    Shamberger, RC
    [J]. JOURNAL OF PEDIATRIC SURGERY, 2005, 40 (06) : 999 - 1003
  • [7] Inflammatory myoblastic tumor of the uterus and interleukin-6
    Azuno, Y
    Yaga, K
    Suehiro, Y
    Ariyama, S
    Oga, A
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (03) : 890 - 891
  • [8] The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis
    Baldi, Giacomo Giulio
    Brahmi, Mehdi
    Lo Vullo, Salvatore
    Cojocaru, Elena
    Mir, Olivier
    Casanova, Michela
    Vincenzi, Bruno
    De Pas, Tommaso Martino
    Grignani, Giovanni
    Pantaleo, Maria Abbondanza
    Blay, Jean Yves
    Jones, Robin Lewis
    Le Cesne, Axel
    Frezza, Anna Maria
    Gronchi, Alessandro
    Collini, Paola
    Dei Tos, Angelo Paolo
    Morosi, Carlo
    Mariani, Luigi
    Casali, Paolo Giovanni
    Stacchiotti, Silvia
    [J]. ONCOLOGIST, 2020, 25 (11) : E1777 - E1784
  • [9] Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor
    Bridge, JA
    Kanamori, M
    Ma, ZG
    Pickering, D
    Hill, DA
    Lydiatt, W
    Lui, MY
    Colleoni, GWB
    Antonescu, CR
    Ladanyi, M
    Morris, SW
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) : 411 - 415
  • [10] ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects
    Brivio, Erica
    Zwaan, C. Michel
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 (05)
12345678910